Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
56.41
+0.50 (0.89%)
At close: Jul 19, 2024, 4:00 PM
56.42
+0.01 (0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $3.75M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $835.00K. In the year 2023, Cytokinetics had annual revenue of $7.53M.
Revenue (ttm)
$3.75M
Revenue Growth
-96.17%
P/S Ratio
1,723.84
Revenue / Employee
$8,870
Employees
423
Market Cap
6.47B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
Dec 31, 2005 | 8.91M | -4.53M | -33.70% |
Dec 31, 2004 | 13.44M | 2.87M | 27.09% |
Dec 31, 2003 | 10.58M | -819.00K | -7.19% |
Dec 31, 2002 | 11.40M | 2.93M | 34.61% |
Dec 31, 2001 | 8.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
Elanco Animal Health | 4.37B |
Jazz Pharmaceuticals | 3.84B |
Exelixis | 1.85B |
HealthEquity | 1.04B |
Halozyme Therapeutics | 862.99M |
Repligen | 607.45M |
Tempus AI | 562.02M |
CYTK News
- 18 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants - GlobeNewsWire
- 6 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Cytokinetics to Participate in June Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cytokinetics Announces Closing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline - GlobeNewsWire